Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX

Pharmacology Biochemistry and Behavior

Volumn 94, Issue 4, 2010, Pages 561-569

  Collins, Lyndsey E ^a   Galtieri, Daniel J ^a   Brennum, Lise T ^b   Sager, Thomas N ^b   Hockemeyer, Jörg ^c   Müller, Christa E ^c   Hinman, James R ^a   Chrobak, James J ^a   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Acetylcholine; Dopamine; In vivo binding; Neostriatum; Parkinsonism; Tremor

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; MSX 3; PILOCARPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; IN VIVO STUDY; JAW MOVEMENT; MALE; NONHUMAN; PERIORAL TREMOR; PRIORITY JOURNAL; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; JAW; MALE; MUSCARINIC AGONISTS; PILOCARPINE; PIMOZIDE; PYRIMIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; TREMOR; TRIAZOLES; XANTHINES;

RATTUS;

EID: 74249086846     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.11.011     Document Type: Article

References (104)

1. Aarsland D., Hutchison M., and Larsen J.P. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriat Psychiat 18 (2003) 937-941
2. Alkelai A., Greenbaum L., Rigbi A., Kanyas K., and Lerer B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology 206 (2009) 491-499
3. Aoyama S., Kase H., and Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 20 (2000) 5848-5852
4. Aquilonius S.M. Cholinergic mechanisms in the CNS related to Parkinson's disease. Parkinson's disease-current progress, problems and management (1980), Elsevier, North Holland, Amsterdam
5. Arai M. Parkinsonism onset in a patient concurrently using tiapride and donepezil. Intern Med 39 (2000) 863
6. Aubel B., Kayser V., Farré A., Hamon M., and Bourgoin S. Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy. Neuropharmacology 52 (2007) 487-496
7. Avila I., Reilly M.P., Sanabria F., Posadas-Sánchez D., Chavez C.L., Banerjee N., et al. Modeling operant behavior in the Parkinsonian rat. Behav Brain Res 198 (2009) 298-305
8. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
9. Baskin P., and Salamone J.D. Vacuous jaw movements in rats induced by acute reserpine administration: interactions with different doses of apomorphine. Pharmacol Biochem Behav 46 (1993) 793-797
10. Bekar L., Libionka W., Tian G.F., Xu Q., Torres A., Wang X., et al. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nat Med 14 (2008) 75-80
11. Bergman H., and Deuschl G. Pathophysiology of Parkinson's Disease: from clinical neurology to basic neuroscience and back. Mov Disord 17 suppl. 3 (2002) s28-s40
12. Betz A., Ishiwari K., Wisniecki A., Huyn N., and Salamone J.D. Quetiapine (Seroquel) shows a pattern of behavioral effects similar to the atypical antipsychotics clozapine and olanzapine: studies with tremulous jaw movements in rats. Psychopharmacology 179 (2005) 383-392
13. Betz A.J., McLaughlin P.J., Burgos M., Weber S.M., and Salamone J.D. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology 194 (2007) 347-359
14. 2A antagonist KW-6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 163 (2009) 97-108
15. Bourke D., and Drukenbrod R.W. Possible association between donepezil and worsening Parkinson's disease. Ann Pharmacother 32 (1998) 610-611
16. Brimblecombe R.W. Review of tremorogenic agents. In: Walter P.G. (Ed). Cholinergic mechanisms (1975), Raven Press, New York 405-410
17. Cabeza-Alvarez C.I., Gonzolez-Rubio M., Carcia Montero R., and Alvarez-Tejerina A. Parkinsonism syndrome related to tacrine. Neurologia 14 (1999) 96
18. Castañeda E., Fleming S., Paquette M.A., Boat K., Moffett J., Stachowiak E.K., et al. Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate. Physiol Behav 84 (2005) 525-535
19. Cenci M., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nature Neurosci Rev 3 (2002) 574-579
20. 2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148 (2004) 47-54
21. Cousins M.S., Carriero D.L., and Salamone J.D. Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol 322 (1997) 137-145
22. Cousins M.S., Atherton A., and Salamone J.D. Behavioral and electromyographic characterization of the local frequency of tacrine-induced tremulous jaw movements. Physiol Behav 64 (1998) 153-158
23. Delong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13 (1990) 281-285
24. Deuschl G., Raethjen J., Lindemann M., and Krack P. The pathophysiology of tremor. Muscle Nerve 24 (2001) 716-735
25. Dronfield S., Egan K., Marsden C.A., and Green A.R. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat. J Psychopharmacol 14 (2000) 275-279
26. Duvoisin R. Cholinergic-anticholinergic antagonism in Parkinsonism. Arch Neurol 17 (1967) 124-136
27. Ferré S., Freidholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20 (1997) 482-487
28. Ferré S., Popoli P., Gimenez-Llort L., Rimondini R., Müller C.E., Stromberg I., et al. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinson Rel Disord 7 (2001) 235-241
29. Ferré S., Ciruela F., Canals M., Marcellino D., Burgueno J., Casado V., et al. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord 10 (2004) 265-271
30. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res 14 (1992) 186-195
31. Finn M., Jassen A., Baskin P., and Salamone J.D. Tremulous characteristics of the vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol Biochem Behav 57 (1997) 243-249
32. Fuxe K., Ferré S., Genedani S., Franco R., and Agnati L.F. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav 92 (2007) 210-217
33. Gurevich T.Y., Shabtai H., Korczyn A.D., Simon E.S., and Giladi N. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Mov Disord 21 (2006) 1663-1666
34. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog Neurobiol 56 (1998) 507-540
35. Hauber W., Neuscheler P., Nagel J., and Müller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2a receptors in the caudate putamen of rats. Eur J Neurosci 14 (2001) 1287-1293
36. 4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 14 (1994) 3351-3363
37. Hockemeyer J., Burbiel J.C., and Müller C.E. Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem 69 (2004) 3308-3318
38. Hornykiewicz O. Dopamine in the basal ganglia. Br Med Bull 29 (1973) 172-178
39. Ince E., Ciliax B.J., and Levey A.I. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27 (1997) 357-366
40. Ishiwari K., Betz A., Weber S., Felsted J., and Salamone J.D. Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats. Pharmacol Biochem Behav 80 (2005) 351-362
41. 2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behav Brain Res 178 (2007) 190-199
42. Iwasaki Y., Wakata N., and Kinoshita M. Parkinsonism induced by pyridostigmine. Acta Neurol Scand 78 (1988) 236
43. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Exp Opin Investig Drugs 14 (2005) 729-738
44. Jicha G.A., and Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms. J Neurosci 11 (1991) 3822-3829
45. Kao K.P., Kwan S.Y., Lin K.P., and Chang Y.C. Coexistence of Parkinson's disease and myasthenia gravis: a case report. Clin Neurol Neurosurg 95 (1993) 137-139
46. Keltner N.L. Tacrine: a pharmacological approach to Alzheimer's disease. J Psychosoc Nurs Ment Health Serv 32 (1994) 37-39
47. Keppel G. Design and analysis: a researcher's handbook (1991), Prentice Hall
48. LeWitt P.A., Guttman M., Tetrud J.W., Tuite P.J., Mori A., Chaikin P., et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63 (2008) 295-302
49. Liston D.R., Nielsen J.A., Villalobos A., Chapin D., Jones S.B., Hubbard S.T., et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 486 (2004) 9-17
50. Lobato K.R., Binfaré R.W., Budni J., Rosa A.O., Santos A.R., and Rodrigues A.L. Involvement of the adenosine A1 and A2A receptors in the antidepressant-like effect of zinc in the forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 994-999
51. Maemoto T., Finlayson K., Olverman H.J., Akahane A., Horton R.W., and Butcher S.P. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists. Br J Pharmacol 122 (1997) 1202-1208
52. Maione S., de Novellis V., Cappellacci L., Palazzo E., Vita D., Luongo L., et al. The antinociceptive effect of 2-chloro-2′-C-methyl-N6-cyclopentyladenosine (2′-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat. Pain 131 (2007) 281-292
53. Mally J., and Stone T.W. Potential role of adenosine antagonist therapy in pathological tremor disorders. Pharmacol Ther 72 (1996) 243-250
54. Mally J., and Stone T.W. Potential of adenosine A2A antagonists in the treatment of movement disorders. CNS Drugs 10 (1998) 311-320
55. Marsden C., Duvoisin R., Jenner P., Parkes J., Pycock C., and Tarsy D. Relationship between animal models and clinical parkinsonism. Adv Neurol 9 (1975) 165-175
56. Marston H.M., Finlayson K., Maemoto T., Olverman H.J., Akahane A., Sharkey J., et al. Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques. J Pharmacol Exp Ther 285 (1998) 1023-1030
57. Matsuya T., Takuma K., Sato K., Asai M., Murakami Y., Miyoshi S., et al. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. J Pharmacol Sci 103 (2007) 329-332
58. Mayorga A.J., Carriero D.L., Cousins M.S., Gianutsos G., and Salamone J.D. Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects. Pharmacol Biochem Behav 56 (1997) 273-279
59. McEvoy J.P. The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 3 (1983) 288-301
60. McSwain M.L., and Forman L.M. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol. J Clin Psychopharmacol 15 (1995) 284
61. Miwa H. Rodent models of tremor. Cerebellum 6 (2007) 66-72
62. Miwa H., Hama K., Kajimoto Y., and Kondo T. Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat Disord 14 (2008) 33-36
63. Miwa H., Kubo T., Suzuki A., and Kondo T. Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect. Parkinsonism Relat Disord 15 (2009) 30-35
64. 2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 22 (2002) 71-72
65. Mott A.M., Nunes E.J., Collins L.E., Port R.G., Sink K.S., Hockemeyer J., et al. The adenosine A(2A) antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology 204 (2009) 103-112
66. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzolo N., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 (2000) S8-S19
67. Ott B.R., and Lannon M.C. Exacerbation of Parkinsonism by tacrine. Clin Neuropharm 15 (1992) 322-325
68. Pinna A., Wardas J., Simola N., and Morelli M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci 77 (2005) 3259-3267
69. Pollack A.E., and Fink J.S. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 743 (1996) 124-130
70. Pollack A.E., and Thomas L.I. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats. Pharmacol Biochem Behav 94 (2010) 346-351
71. Prediger R.D., and Takahashi R.N. Modulation of short-term social memory in rats by adenosine A1 and A(2A) receptors. Neurosci Lett 376 (2005) 160-165
72. Prediger R.D., Fernandes D., and Takahashi R.N. Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behav Brain Res 159 (2005) 197-205
73. Rimondini R., Ferré S., Giménez-Llort L., Ogren S.O., and Fuxe K. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur J Pharmacol 347 (1998) 153-158
74. Rodriguez Diaz M., Abdala P., Barroso-Chinea P., Obeso J., and Gonzalez-Hernandez T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopaminein the rat: an animal model of Parkinson's disease. Behav Brain Res 122 (2001) 79-92
75. Rosin D.L., Robeva A., Woodard R.L., Guyenet P.G., and Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 401 (1998) 163-186
76. Salamone J., and Baskin P. Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Pharmacol Biochem Behav 53 (1996) 179-183
77. Salamone J.D., Lalies M.D., Channell S.L., and Iversen S.D. Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology 88 (1986) 467-471
78. Salamone J.D., Johnson C.J., McCullough L.D., and Steinpreis R.E. Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology 102 (1990) 529-534
79. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., and Nawab A. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56 (1998) 591-611
80. Salamone J., Correa M., Carlson B., Wisniecki A., Mayorga A., Nisenbaum E., et al. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents. Implications for cholinergic involvement in parkinsonism. Life Sci 68 (2001) 2579-2584
81. Salamone J.D., Carlson B.B., Rios C., Lentini E., Correa M., Wisniecki A., et al. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behav Brain Res 156 (2005) 173-179
82. Salamone J.D., Betz A.J., Ishiwari K., Felsted J., Madson L., Mirante B., et al. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci 13 (2008) 3594-3605
83. Salamone J.D., Ishiwari K., Betz A.J., Farrar A.M., Mingote S.M., Font L., et al. Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism Relat Disord 14 (2008) S130-S134
84. Salamone J.D., Farrar A.M., Font L., Patel V., Schlar D.E., Nunes E.J., et al. Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behav Brain Res 201 (2009) 216-222
85. Sauer R., Maurinsh J., Reith U., Fulle F., Klotz K.N., and Muller C.E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J Med Chem 43 (2000) 440-448
86. Schiffman S.N., Jacobs O., and Vanderhaeghen J.J. The striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in-situ hybridization study. J Neurochem 57 (1991) 1062-1067
87. Schwarzschild M.A., Chen J.F., and Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 58 (2002) 1154-1160
88. Shea C., MacKnight C., and Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10 (1998) 229-238
89. Simola N., Fenu S., Baraldi P.G., Tabrizi M.A., and Morelli M. Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 189 (2004) 182-188
90. Simola N., Fenu S., Baraldi P.G., Tabrizi M.A., and Morelli M. Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. J Neurol Sci 248 (2006) 48-52
91. Song I.U., Kim J.S., Ryu S.B., An J.Y., and Lee K.S. Donepezil-induced jaw tremor. Parkinson Rel Disord 14 (2008) 584-585
92. Steinpreis R.E., Baskin P., and Salamone J.D. Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology 111 (1993) 99-105
93. Stewart B.R., Jenner P., and Marsden C.D. The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat. Psychopharmacology 96 (1988) 55-62
94. Stromberg I., Popoli P., Muller C.E., Ferre S., and Fuxe K. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in dopamine-denervated striatum. Eur J Neurosci 12 (2000) 4033-4037
95. Svenningsson P., Le Moine C., Fisone G., and Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 59 (1999) 355-396
96. Trevitt J., Atherton A., Aberman J., and Salamone J.D. Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology 137 (1998) 61-66
97. Trevitt J., Vallance C., Harris A., and Goode T. Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease. Pharmacol Biochem Behav 92 (2009) 521-527
98. Trevitt J., Kawa K., Jalali A., and Larsen C. Differential effects of adenosine antagonists in two models of parkinsonian tremor. Pharmacol Biochem Behav 94 (2009) 24-29
99. Tronci E., Simola N., Borsini F., Schintu N., Frau L., Carminati P., et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol 566 (2007) 94-102
100. 2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 90 (2008) 540-544
101. Varty G.B., Hodgson R.A., Pond A.J., Grzelak M.E., Parker E.M., and Hunter J.C. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates. Psychopharmacology 200 (2008) 393-401
102. Wardas J., Konieczny J., and Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41 (2001) 160-171
103. Wilms H., Sievers J., and Deuschl G. Animal models of tremor. Mov Disord 14 (1999) 557-571
104. Young A., and Penney J. In: Jankovic J., and Tolosa E. (Eds). Parkinson's disease and movement disorders (1993), Williams & Wilkins, Baltimore